The Australian company is now looking for partners with a positive interim analysis of data from the ACTION3 Phase 3 trial of DMX-200 in patients with a debilitating kidney disease.
Dimerix's DMX-200 successfully passes interim analysis in ACTION3 Phase 3 trial
March 11, 2024 Australian Biotech
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News